RiverVest Funds I, II & III RiverVest Fund IV Archer Seed Fund

16 Apr

Posted at 20:49h in by

/ PORTFOLIO /*! elementor - v3.21.0 - 08-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAEngrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience.  The company is committed to rapidly advancing its innovative, precision-targeted therapeutics for the...

15 Aug

Posted at 13:39h in by

/ PORTFOLIO /*! elementor - v3.17.0 - 25-10-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WABonum is a biopharma company developing immuno-oncology drugs exclusively active within the tumor micro-environemnt.BONUMTX.COM © Copyright RiverVest® All Rights Reserved....

02 May

Posted at 20:13h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAMaxwell Biomedical is developing a first-of-its-kind device-based solution designed to maintain sinus rhythm in patients with Atrial Fibrillation (AFib).MAXWELLBIOMEDICAL.COM © Copyright RiverVest® All Rights Reserved....

23 Jan

Posted at 00:00h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Austin, TXAlleviant Medical, Inc. is a medical device company developing a minimally invasive, implant-free interatrial shunt device under clinical investigation for the treatment of chronic heart failure. The Alleviant System was granted U.S. FDA Breakthrough...

14 Dec

Posted at 15:37h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAvalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The lead asset is inhaled pirfenidone (Aerodone™) for the treatment of...

14 Dec

Posted at 15:28h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Boston, MAXilio is an oncology company developing highly-potent, tumor-selective immunotherapies to improve patient outcomes. With an anti-CTLA4 antibody as validation, the company’s technology is also being applied to cytokines, which currently have limited or...

14 Dec

Posted at 15:14h in by

/ PORTFOLIO /*! elementor - v3.19.0 - 26-02-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAInterVene is focused on re-canalizing chronic post-thrombotic venous occlusions with its Chronus device. Initially focused on in-stent restenosis, Chronus represents a unique modality designed to restore patency in difficult deep vein lesions.INTERVENE-MED.COM ©...

14 Dec

Posted at 15:06h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAOncoResponse is leveraging a proprietary human antibody platform to discover novel targets and identify fully-human monoclonal antibodies as therapeutics for the treatment of cancer, potentially extending cures to patients who otherwise would not...

14 Dec

Posted at 15:04h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOOxaluRx is a preclinical company developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease. This rare form of hyperoxaluria is due exclusively to a genetic defect...

14 Dec

Posted at 15:03h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAIPO April 2021 (NASDAQ: RPHM)Reneo, a RiverVest-founded company, is a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with...

14 Dec

Posted at 14:58h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CAIPO October 2020 (NASDAQ: SPRB)Spruce is developing novel therapies for rare endocrine diseases. The company’s lead product candidate for the treatment of congenital adrenal hyperplasia (CAH) is intended to correct hormone imbalances,...

14 Dec

Posted at 14:29h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Minneapolis, MNVentureMed develops and markets innovative medical devices for the treatment of peripheral vascular disease (PAD) and stenosis of arteriovenous (AV) fistulas and grafts, serious conditions leading to reduced blood flow and many complications....

14 Dec

Posted at 14:20h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWugen is developing a novel chimeric antigen receptor (CAR-T) therapy platform for T-cell malignancies. Wugen’s state-of-the-art gene editing and CAR-T cell technology enable “off-the-shelf” therapies that would avoid rejection by the recipient....

13 Dec

Posted at 20:50h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Portland, ORSparrow Pharmaceuticals was founded to spare patients the ravages of corticosteroids. Leveraging underappreciated scientific insights into steroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and...

13 Dec

Posted at 20:48h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Carlos, CAGlycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes,...

13 Dec

Posted at 20:45h in by

/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Waltham, MASeQure Dx, Inc. is applying state-of-the-art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their core technologies, GUIDE-seq and ONE-seq, enable identification of all potential off-target...